Market Cap 12.81B
Revenue (ttm) 8.25B
Net Income (ttm) 478.00M
EPS (ttm) N/A
PE Ratio 12.44
Forward PE 12.24
Profit Margin 5.79%
Debt to Equity Ratio 1.03
Volume 1,341,200
Avg Vol 1,066,906
Day's Range N/A - N/A
Shares Out 173.45M
Stochastic %K 92%
Beta 0.48
Analysts Sell
Price Target $84.50

Company Profile

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates in four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers solutions for negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature m...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 651 733 1110
Address:
3M Center, Building 275-6W-20 2510 Conway Avenue East St. Paul, Maplewood, United States
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:48 AM
$SOLV is currently trading at $75.22, showing a bullish sentiment as the RSI is at 61.65, indicating upward momentum but not yet overbought. The price is above both the 30-day MA (71.41) and the 50-day MA (72.08), confirming a positive trend. The recent high of $75.98 suggests potential resistance, while the low of $66.11 provides a solid support level. Directional bias is bullish due to the price action above the moving averages and the RSI indicating strength. Suggested entry is at $75.30 to capture momentum. Set a stop loss at $73.50 to manage risk, below the 50-day MA. Targets can be set at $77.00 (near the 60D high) and $78.50 (a psychological resistance level). Monitor for any changes in momentum or market conditions that could affect these levels. https://privateprofiteers.com
0 · Reply
Mrstock2255
Mrstock2255 Nov. 14 at 1:26 AM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:55 AM
$SOLV is currently trading at $73.9, showing a stable position with an RSI of 53.53, indicating neutral momentum. The price is above the 30-day MA of 71.37 and the 50-day MA of 71.98, suggesting a bullish trend in the short to medium term. The recent high of $75.6 is within reach, providing a potential target for upward movement. Market context shows that the price is closer to the recent high than the low of $66.11, reinforcing a bullish bias. Given the ATR of 1.85, there is moderate volatility, allowing for reasonable price movement. Suggested trade plan: - Entry: $74.00 (slightly above the last close) - Stop: $71.50 (below the 30-day MA for safety) - Target 1: $75.00 (near the 60D high) - Target 2: $76.00 (further upside potential) Monitor the RSI for any divergence and adjust the stop accordingly. Maintain awareness of market conditions. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:31 AM
$SOLV is currently trading at $73.9, showing a stable position with an RSI of 53.53, indicating neutral momentum. The price is above the 30-day MA of 71.37 and the 50-day MA of 71.98, suggesting a bullish trend in the short to medium term. The recent high of $75.6 is within reach, providing a potential target for upward movement. Market context shows that the price is closer to the recent high than the low of $66.11, reinforcing a bullish bias. Given the ATR of 1.85, there is moderate volatility, allowing for reasonable price movement. Suggested trade plan: - Entry: $74.00 (slightly above the last close) - Stop: $71.50 (below the 30-day MA for safety) - Target 1: $75.00 (near the 60D high) - Target 2: $76.00 (further upside potential) Monitor the RSI for any divergence and adjust the stop accordingly. Maintain awareness of market conditions. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 7:49 PM
UBS updates rating for Solventum ( $SOLV ) to Neutral, target set at 77 → 79.
0 · Reply
AirForce7
AirForce7 Nov. 10 at 9:53 AM
$SOLV -9% ??????????
1 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 12:46 PM
Piper Sandler has adjusted their stance on Solventum ( $SOLV ), setting the rating to Overweight with a target price of 94 → 98.
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 5 at 3:02 PM
$SOLV Current Stock Price: $67.64 Contracts to trade: $70 SOLV Nov 21 2025 Call Entry: $1.57 Exit: $2.30 ROI: 46% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ZacksResearch
ZacksResearch Nov. 3 at 1:15 PM
Healthcare stocks set to shine in Q3! 💡 🔍 $SOLV boasts a Zacks Rank #1 with an Earnings ESP of +0.88%, expecting an EPS of $1.43 despite a forecasted 12.8% decline. 🔍 $COR, with a Zacks Rank #3, has an Earnings ESP of +0.31%, with the Zacks Consensus Estimate for EPS pegged at $3.79, implying growth of 13.5%. 🔍 $INSP shows a staggering +80.22% Earnings ESP, a Zacks Rank #3, and a projected EPS loss of 15 cents, indicating a decline of 125%. See the full potential here 👉 https://www.zacks.com/stock/news/2783251/3-medtech-stocks-positioned-to-surpass-q3-earnings-estimates?cid=sm-stocktwits-2-2783251-body-18994&ADID=SYND_STOCKTWITS_TWEET_2_2783251_BODY_18994
0 · Reply
ZacksResearch
ZacksResearch Nov. 3 at 12:15 PM
Innovation could trump inflation for $SOLV, $COR & $INSP this quarter 🔥 Breakthroughs in diabetes care, surgical tech, and cardiovascular devices are setting the stage for potential earnings beats — even with tariff and inflation headwinds in play. Find out which of these MedTech names could outperform 👉 https://www.zacks.com/stock/news/2783251/3-medtech-stocks-positioned-to-surpass-q3-earnings-estimates?cid=sm-stocktwits-2-2783251-teaser-18993&ADID=SYND_STOCKTWITS_TWEET_2_2783251_TEASER_18993
0 · Reply
Latest News on SOLV
Solventum Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 7 days ago

Solventum Reports Third Quarter 2025 Financial Results


Solventum: A Solid Performance Here

Oct 22, 2025, 12:42 PM EDT - 22 days ago

Solventum: A Solid Performance Here


Solventum Appoints Heather Knight as Chief Commercial Officer

Oct 21, 2025, 5:00 PM EDT - 23 days ago

Solventum Appoints Heather Knight as Chief Commercial Officer


Solventum to Participate in Upcoming Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 2 months ago

Solventum to Participate in Upcoming Investor Conferences


Solventum Announces $1.75 Billion Note Tender Offers

Aug 22, 2025, 8:19 AM EDT - 3 months ago

Solventum Announces $1.75 Billion Note Tender Offers


Solventum Announces Pricing of Secondary Offering of Common Stock

Aug 13, 2025, 10:39 PM EDT - 3 months ago

Solventum Announces Pricing of Secondary Offering of Common Stock


Solventum Announces Launch of Secondary Offering of Common Stock

Aug 13, 2025, 4:48 PM EDT - 3 months ago

Solventum Announces Launch of Secondary Offering of Common Stock


Solventum Corporation (SOLV) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 6:53 AM EDT - 3 months ago

Solventum Corporation (SOLV) Q2 2025 Earnings Call Transcript


Solventum Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 3 months ago

Solventum Reports Second Quarter 2025 Financial Results


Solventum: Appealing Again

Jul 22, 2025, 9:12 AM EDT - 4 months ago

Solventum: Appealing Again


Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript

May 11, 2025, 5:07 PM EDT - 6 months ago

Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript


Solventum Corporation: Cheap, With Caveats

May 9, 2025, 11:02 AM EDT - 6 months ago

Solventum Corporation: Cheap, With Caveats


Solventum Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 6 months ago

Solventum Reports First Quarter 2025 Financial Results


Solventum Corporation (SOLV) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 8:36 AM EST - 9 months ago

Solventum Corporation (SOLV) Q4 2024 Earnings Call Transcript


Solventum In The Early Stages Of A Multiyear Turnaround Effort

Feb 25, 2025, 10:16 AM EST - 9 months ago

Solventum In The Early Stages Of A Multiyear Turnaround Effort


Trian Issues Open Letter to Solventum Shareholders

Jan 8, 2025, 1:01 PM EST - 11 months ago

Trian Issues Open Letter to Solventum Shareholders


PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:48 AM
$SOLV is currently trading at $75.22, showing a bullish sentiment as the RSI is at 61.65, indicating upward momentum but not yet overbought. The price is above both the 30-day MA (71.41) and the 50-day MA (72.08), confirming a positive trend. The recent high of $75.98 suggests potential resistance, while the low of $66.11 provides a solid support level. Directional bias is bullish due to the price action above the moving averages and the RSI indicating strength. Suggested entry is at $75.30 to capture momentum. Set a stop loss at $73.50 to manage risk, below the 50-day MA. Targets can be set at $77.00 (near the 60D high) and $78.50 (a psychological resistance level). Monitor for any changes in momentum or market conditions that could affect these levels. https://privateprofiteers.com
0 · Reply
Mrstock2255
Mrstock2255 Nov. 14 at 1:26 AM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:55 AM
$SOLV is currently trading at $73.9, showing a stable position with an RSI of 53.53, indicating neutral momentum. The price is above the 30-day MA of 71.37 and the 50-day MA of 71.98, suggesting a bullish trend in the short to medium term. The recent high of $75.6 is within reach, providing a potential target for upward movement. Market context shows that the price is closer to the recent high than the low of $66.11, reinforcing a bullish bias. Given the ATR of 1.85, there is moderate volatility, allowing for reasonable price movement. Suggested trade plan: - Entry: $74.00 (slightly above the last close) - Stop: $71.50 (below the 30-day MA for safety) - Target 1: $75.00 (near the 60D high) - Target 2: $76.00 (further upside potential) Monitor the RSI for any divergence and adjust the stop accordingly. Maintain awareness of market conditions. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:31 AM
$SOLV is currently trading at $73.9, showing a stable position with an RSI of 53.53, indicating neutral momentum. The price is above the 30-day MA of 71.37 and the 50-day MA of 71.98, suggesting a bullish trend in the short to medium term. The recent high of $75.6 is within reach, providing a potential target for upward movement. Market context shows that the price is closer to the recent high than the low of $66.11, reinforcing a bullish bias. Given the ATR of 1.85, there is moderate volatility, allowing for reasonable price movement. Suggested trade plan: - Entry: $74.00 (slightly above the last close) - Stop: $71.50 (below the 30-day MA for safety) - Target 1: $75.00 (near the 60D high) - Target 2: $76.00 (further upside potential) Monitor the RSI for any divergence and adjust the stop accordingly. Maintain awareness of market conditions. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 7:49 PM
UBS updates rating for Solventum ( $SOLV ) to Neutral, target set at 77 → 79.
0 · Reply
AirForce7
AirForce7 Nov. 10 at 9:53 AM
$SOLV -9% ??????????
1 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 12:46 PM
Piper Sandler has adjusted their stance on Solventum ( $SOLV ), setting the rating to Overweight with a target price of 94 → 98.
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 5 at 3:02 PM
$SOLV Current Stock Price: $67.64 Contracts to trade: $70 SOLV Nov 21 2025 Call Entry: $1.57 Exit: $2.30 ROI: 46% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ZacksResearch
ZacksResearch Nov. 3 at 1:15 PM
Healthcare stocks set to shine in Q3! 💡 🔍 $SOLV boasts a Zacks Rank #1 with an Earnings ESP of +0.88%, expecting an EPS of $1.43 despite a forecasted 12.8% decline. 🔍 $COR, with a Zacks Rank #3, has an Earnings ESP of +0.31%, with the Zacks Consensus Estimate for EPS pegged at $3.79, implying growth of 13.5%. 🔍 $INSP shows a staggering +80.22% Earnings ESP, a Zacks Rank #3, and a projected EPS loss of 15 cents, indicating a decline of 125%. See the full potential here 👉 https://www.zacks.com/stock/news/2783251/3-medtech-stocks-positioned-to-surpass-q3-earnings-estimates?cid=sm-stocktwits-2-2783251-body-18994&ADID=SYND_STOCKTWITS_TWEET_2_2783251_BODY_18994
0 · Reply
ZacksResearch
ZacksResearch Nov. 3 at 12:15 PM
Innovation could trump inflation for $SOLV, $COR & $INSP this quarter 🔥 Breakthroughs in diabetes care, surgical tech, and cardiovascular devices are setting the stage for potential earnings beats — even with tariff and inflation headwinds in play. Find out which of these MedTech names could outperform 👉 https://www.zacks.com/stock/news/2783251/3-medtech-stocks-positioned-to-surpass-q3-earnings-estimates?cid=sm-stocktwits-2-2783251-teaser-18993&ADID=SYND_STOCKTWITS_TWEET_2_2783251_TEASER_18993
0 · Reply
ismellcashcoming
ismellcashcoming Oct. 31 at 1:13 PM
0 · Reply
PaperHandedPanicSeller
PaperHandedPanicSeller Oct. 30 at 10:50 PM
$SOLV & $JZXN 🚀🚀🚀 https://coincentral.com/jiuzi-holdings-inc-jzxn-stock-soars-on-1b-bitcoin-defi-partnership-with-solv-foundation/
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 28 at 12:02 PM
$SOLV Share Price: $71.99 Contract Selected: Apr 17, 2026 $70 Calls Buy Zone: $6.43 – $7.94 Target Zone: $12.00 – $14.67 Potential Upside: 76% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
bigbulldaddy
bigbulldaddy Oct. 27 at 11:41 PM
$SOLV Something is in the process of getting acquired right now. There was a major managers meeting last week where they signed NDAs. Also 5 managers were strategically let go. Nobody is talking but it’s obvious what’s happening. Something that impacts territories alignments and products for 2026 for at least 200 - 500 reps. I’m not sure how good or bad of a thing it is. More info will probably drop within 1-2 months. They are using part of the 4 billion purification sale to do this vs paying off debt solely (which they stated was there plan for an acquisition). Also company is opening up employee stock purchase program in January which should help prop up the stock price with 1000s of employees purchasing shares at 15% market discount. This should at least be bullish for share price.
1 · Reply
bigbulldaddy
bigbulldaddy Oct. 24 at 4:28 PM
$SOLV In the gutter on a Green Day.
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 21 at 1:29 PM
$SOLV Share Price: $72.87 Contract Selected: Apr 17, 2026 $75 Calls Buy Zone: $4.18 – $5.17 Target Zone: $7.12 – $8.71 Potential Upside: 61% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 7:58 AM
Enter: $SOLV NOV 21 2025 $75 CALLS Buy in Price: $1.75 - $3.50 Take Profit: $3.18 Stop Bleeding: $1.54 ROI Potential: 82% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
Myturn
Myturn Oct. 15 at 12:09 PM
$MARA $SOLV $ZNB The journey to $MARA play started with the today’s PR of the $231 Million Bitcoin-Backed Private Placement!
0 · Reply
Myturn
Myturn Oct. 14 at 1:20 AM
$ZNB is becoming like a $MARA play where MARA’s primary business is Bitcoin mining, and it also acquires and holds digital assets (e.g. Bitcoin) as part of its corporate treasury strategy — as ZNB has been doing and clarified its crypto treasury strategy besides mining last week! Interestingly, 5 years ago, MARA share price was at 31c only at a market valuation of $2.68 million (with the outstanding shares of only 8.65 million shares) in May 2020 when it announced to start buying additional 10,000 Bitcoin mining machines (like ZNB did in Feb 2025) and completed the purchase in 2021! MARA never saw 31c with market valuation of $2.68 million since then and it is trading at $20 at a whopping market valuation of $7.4 billion! Yes, this a potential future of $ZNB in the coming years! No guarantees, however, with the careful hiring of like Patrick Ngan as Chief Investment Officer and the strategic partner like $SOLV, Potentially Yes!
1 · Reply
Phillvsthemarket
Phillvsthemarket Oct. 7 at 1:50 PM
$ZNB $SPRB $SOLV WHY IN HELL THEY PARTNERED ? Is acting like SPRB
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 3 at 7:35 PM
Enter: $SOLV NOV 21 2025 $75 CALLS Buy in Price: $3.05 - $3.20 Take Profit: $5.61 Stop Bleeding: $2.68 ROI Potential: 84% Exit Within: 67 Minutes https://moneygroup.us/alerts
0 · Reply